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We describe here the selection and characterization of
designed ankyrin repeat proteins (DARPins) that bind
specifically to the rat neurotensin receptor 1 (NTR1), a
G-protein coupled receptor (GPCR). The selection pro-
cedure using ribosome display and the initial clone analy-
sis required <10 mg of detergent-solubilized, purified
NTR1. Complex formation with solubilized GPCR was
demonstrated by ELISA and size-exclusion chromato-
graphy; additionally, the GPCR could be detected in
native membranes of mammalian cells using fluorescence
microscopy. The main binding epitope in the GPCR lies
within the 33 amino acids following the seventh trans-
membrane segment, which comprise the putative helix 8,
and additional binding interactions are possibly contribu-
ted by the cytoplasmic loop 3, thus constituting a discon-
tinuous epitope. Since the selected binders recognize the
GPCR both in detergent-solubilized and in membrane-
embedded forms, they will be potentially useful both in
co-crystallization trials and for signal transduction
experiments.
Keywords: DARPins/GPCR/neurotensin/NTR1/ribosome
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Introduction
The neurotensin receptor 1 (NTR1) is a G-protein coupled
receptor (GPCR) (Kroeze et al., 2003; Leifert et al., 2005)
found in the central nervous system and in the gastrointesti-
nal tract. Depending on the cell type and the ligand, it can
couple, with varying efficiencies, to all three G-protein sub-
types, Gs, Gi and Gq, generating a wide diversity of func-
tional responses (Pelaprat, 2006). Its physiological ligand, the
tridecapeptide neurotensin (NT), exerts a variety of beha-
vioral and hormonal effects, including regulation of body
temperature as well as inhibition of nociception and food
intake. NTR1 ligands have potential therapeutic utility in the
treatment of psychiatric and neurological disorders such as
schizophrenia, Parkinson’s disease and drug addiction
(Boules et al., 2006). NT is, however, readily degraded by
peptidases, and hence there is great interest in finding
protease-resistant NT-analogs able to cross the blood–brain
barrier (Boules et al., 2006). NT and its analogs also partici-
pate in the growth of cancer cells, and thus the receptor can
be used for tumor imaging with NT analogs (Carraway and
Plona, 2006). Despite the physiological and clinical rel-
evance of NTR1, no structural information about this
membrane-bound receptor is currently available.
Membrane proteins are intrinsically very difficult to
crystallize and this is reflected by the small number of
solved membrane protein structures, especially of mamma-
lian proteins (www.mpibp-frankfurt.mpg.de/michel/public/
memprotstruct.html, http://blanco.biomol.uci.edu/Membrane_
Proteins_xtal.html). Unlike many other classes of membrane
proteins, GPCRs have no bacterial homologs. The generation
of well-diffracting crystals is primarily hindered by the large
conformational flexibility of the detergent-solubilized mem-
brane protein and the presence of rather small hydrophilic
loops that connect the large hydrophobic segments sur-
rounded by a detergent belt. These sparse polar regions limit
the chances of generating productive intermolecular protein–
protein interactions which mediate crystal growth.
For several years, the only GPCR crystal structure avail-
able was that of bovine rhodopsin (Palczewski et al., 2000),
which can be isolated in fairly large amounts from its native
source, the bovine retina. Only recently have the crystal
structures of three other GPCRs, the closely related b2- and
b1-adrenergic receptors (ARs) (Cherezov et al., 2007;
Rasmussen et al., 2007; Warne et al., 2008) and the adeno-
sine A2A receptor (Jaakola et al., 2008), been determined.
b1AR and A2AR were solved with the help of a soluble
protein partner, either as a complex with a Fab fragment at
3.4 A˚ resolution (Cherezov et al., 2007) or as a fusion with
T4 lysozyme at 2.4 A˚ resolution (Rasmussen et al., 2007;
Jaakola et al., 2008). In both cases, most of the crystal con-
tacts are provided by the soluble protein.
A complementary strategy to increase the conformational
rigidity is to introduce mutations in the receptor itself. This
has been carried out by directed evolution of NTR1 (Sarkar
et al., 2008), which has been improved in thermal stability
by this strategy and is the subject of the present study, and
by alanine scanning on b1AR (Serrano-Vega et al., 2008),
through which a stabilized mutant could be crystallized
(Warne et al., 2008).
Different studies have already shown the use of target-
specific antibody fragments in the co-crystallization with
other membrane proteins (Hunte and Michel, 2002). In all of
these studies, classical immunization was used to generate
the antibodies, with little control over the conformational
state of the detergent-solubilized membrane proteins after
injection into the animal.
In contrast to classical hybridoma technologies, synthetic
libraries and in vitro selection technologies, such as phage
display and ribosome display, can be used to generate such
binding molecules in a fast and reliable way. Since the
binding step is performed in vitro, selection conditions can be
adapted to the need of the target protein (Huber et al., 2007).
We have previously generated recombinant Fab fragments
to the citrate transporter CitS (Ro¨thlisberger et al., 2004).
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Furthermore, recombinant technologies allow the use of
protein classes other than antibodies. We have previously
developed designed ankyrin repeat proteins (DARPins) (Binz
et al., 2003) as an alternative binding molecule for
co-crystallization (Binz et al., 2004; Kohl et al., 2005;
Schweizer et al., 2007), because of their superior biophysical
properties. Ankyrin repeat proteins mediate important
protein–protein interactions in all cellular compartments
(Li et al., 2006) and occur in all phyla. Their modular struc-
ture is built from stacked, 33-amino acid repeats, each
forming a b-turn followed by two antiparallel a-helices and
a loop connecting to the b-turn of the next repeat. A
DARPin library, conserving the structure-determining resi-
dues and varying the potential interaction residues, was built
(Binz et al., 2003) in which varying numbers of designed
ankyrin repeats (typically 2 or 3), which carry the binding
interface, are cloned in between specialized N- and
C-terminal capping-repeats. These DARPins are termed N2C
and N3C, where the number denotes how many internal
repeats are present.
DARPins are obtained in very high yields (typically 100–
200 mg soluble purified protein per liter Escherichia coli
shake flask culture), and they tolerate the presence of redu-
cing agents, as DARPins do not contain any disulfide bonds
or free cysteines. They have a rather shallow groove-like
binding surface, which is complementary to folded proteins.
Therefore, both the molecular design and the in vitro
selection strategy significantly increase the likelihood of
obtaining binders against structural epitopes, rather than
unstructured tails. Another very important advantage of
DARPins is their high thermodynamic stability (Wetzel
et al., 2008), which allows them to retain function even in
harsh environments, such as detergent solutions (Huber
et al., 2007).
DARPins can be selected both by ribosome display and by
phage display (Binz et al., 2004; Steiner et al., 2008), and
they have already been selected against integral membrane
proteins using both methods (Huber et al., 2007) (A. Batyuk
et al., unpublished results).
In this paper, we describe for the first time DARPins
selected against a GPCR by ribosome display. The initial
characterization of the selected NTR1-specific DARPin
binders required only small amounts (,10 mg) of the mem-
brane receptor. We show that the selected DARPins recog-
nize the GPCR in solubilized form and in the membrane of
mammalian cells.
Materials and methods
Materials
All detergents were obtained from Anatrace, except for
cholesteryl hemisuccinate tris salt (CHS), which was from
Sigma. PCR reactions between the ribosome display rounds
were performed using the Phusion Polymerase from New
England Biolabs (NEB). T7 RNA polymerase was from NEB.
ThermoScript reverse transcriptase was from Invitrogen.
Restriction enzymes were obtained either from NEB or from
Fermentas. The radioligands [3H]-neurotensin and
[methoxy-3H]-SR48692 were from PerkinElmer and GE
Healthcare, respectively. [35S]-Methionine was from Hartmann
Analytic (Braunschweig, Germany). The NTR1 agonist NT
(8–13) and the biotinylated neurotensin (biot-NT), connected
via a 6-aminohexanoic linker, were from AnaSpec (San Jose,
USA). Streptavidin–alkaline phosphatase (SA–AP) conjugate
was from Roche. 5-Bromo-4-chloro-30-indolylphosphate para-
toluidine salt (BCIP) and nitro-blue tetrazolium chloride
(NBT) were from Fluka. Neutravidin was from Pierce.
Protein expression and purification
The N-terminally truncated form of the rat NTR1
(rT43NTR1), missing the first 42 amino acids, was
expressed and purified essentially as described previously
(White et al., 2004), with the main difference that the
E.coli strain XL1-Blue was used in place of DH5a, as it
gave a slightly better yield (data not shown). For simpli-
city, the rT43NTR1 construct will be denoted as NTR1
throughout the paper.
The extract from 30 l of expression culture was loaded
onto 40 ml of Ni-NTA material (Qiagen). For ligand affinity
chromatography, biot-NT (0.8 ml, 100 mM) was immobilized
on a monomeric avidin column (6 ml, Pierce). The prepara-
tive size-exclusion chromatography (SEC) was performed on
a HiLoad 16/60 Superdex 200 prep grade column (GE
Healthcare). Fractions from the gel filtration column were
shock frozen in liquid nitrogen and stored at 2808C. The
active fraction of the purified receptor was quantitated in a
radioligand binding assay according to the manufacturer’s
instructions with Bio-Spin 30 spin-columns (Bio-Rad) to
remove the excess of [3H]-labeled ligand. The radioactive
samples were analyzed by liquid scintillation counting. The
total receptor concentration was measured using the
DC-assay (Bio-Rad). We isolated 0.3 mg of active solubil-
ized wild-type NTR1 from 30 l of expression culture before
a mutant evolved for expression and stability became avail-
able (Sarkar et al., 2008). Before an experiment, the gel fil-
tration fractions were thawed on ice, and the active portion
was determined to be 50–70% of the total receptor con-
centration. The receptor was subsequently immobilized via
its ligand (see below), ensuring that only active receptor is
retained.
The biotinylated DARPins were obtained using the
plasmid pAT223 (Amstutz et al., 2005) (GenBankTM acces-
sion number AY327138). The expressed polypeptide carries
an N-terminal Avi-tag for in vivo biotinylation, followed by
the phage l protein D (pD) and a His6-tag for purification
and, at the C-terminus, the DARPin. In vivo biotinylation
was performed according to protocols from Avidity (Denver,
CO, USA) and Qiagen in E.coli XL1-Blue cells (Stratagene,
La Jolla, CA, USA) transformed with both the pBirAcm
(Avidity) and the pAT223-DARPin plasmids. Successful bio-
tinylation of the IMAC purified proteins was confirmed by
using the 40-hydroxyazobenzene-2-carboxylic acid assay
(Pierce), and by western blot using an SA–AP conjugate
(Roche Applied Science). Non-biotinylated DARPins were
produced using pAT223 and E.coli XL1-Blue while omitting
the pBirAcm plasmid and biotin, reducing biotinylation (by
genomically encoded BirA) to 1%.
The DARPin constructs with an N-terminal RGSH6-tag
and 5 myc-tags at the C-terminus were expressed in
E.coli XL1-Blue from a pQE30-based vector (Huber
et al., 2007) and then purified using Ni-NTA affinity
chromatography.
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Ribosome display
The PCR-amplified DARPin N2C and N3C libraries were
transcribed and the ribosome display selections were per-
formed as previously described (Hanes and Plu¨ckthun, 1997;
Huber et al., 2007; Zahnd et al., 2007) with a few modifi-
cations. The main difference is the presence of 0.5%
CHAPS, 0.1% CHS, 0.1% DDM during the translation reac-
tions as well as the binding and washing steps. According to
previous studies (Tucker and Grisshammer, 1996), this deter-
gent cocktail best preserves the receptor activity.
For a round of ribosome display, MaxiSorp plates/strips
(Nunc) were coated with 66 nM neutravidin (100 ml/well) in
TBS at 48C overnight or for 1 h at 378C. Wells were then
blocked with 0.5% BSA in TBS for 1 h at 30–378C. The
receptor was immobilized by forming a complex between
biot-NT and NTR1, and binding that to the immobilized neu-
travidin. This was achieved by preincubating 15–30 nM of
purified NTR1 with 10–40 nM biot-NT in NTR-buffer
(50 mM Tris, pH 7.4 at 48C, 1 mM EDTA, 0.1% BSA, 0.2%
CHAPS, 0.04% CHS, 0.1% DDM) for 30–60 min at 48C.
The solution was then transferred to the plate for 1 h at 48C.
We used two alternative strategies to remove non-specific
binders from the selection pools. The clones isolated using
the first strategy, pre-panning of the translation mix in wells
lacking the receptor (containing only biot-NT bound to neu-
travidin), are denoted as D-clones. The clones selected using
the second strategy, addition of excess of neutravidin
(500 nM) and biot-NT (40 nM) directly in the buffer used to
stop the translation reactions, are denoted as P-clones.
The translation reactions were stopped with 3–4 volumes
of cold wash buffer WB (50 mM Tris, pH 7.4, 50 mM
MgCl2, 0.5% BSA, 0.5% CHAPS, 0.1% CHS, 0.1% DDM),
transferred to the wells and incubated for 20–30 min. The
solution was then removed and the wells were washed with
WB. The washing time was increased from round to round,
reaching 5 min in the last (fourth) round. After elution of
the bound complexes with a buffer containing 50 mM Tris
(pH 7.5 at 48C), 200 mM NaCl and 50 mM EDTA, the
mRNA was reverse transcribed using ThermoScript reverse
transcriptase and the cDNA was amplified by PCR using
Phusion DNA Polymerase.
Enzyme-linked immunosorbent assays
Neutravidin coating of the MaxiSorp plate and blocking with
BSA was performed as described above. For receptor immo-
bilization, a 30 nM solution of the NTR1/biot-NT complex
was used. For testing specificity, 30 nM solutions of biotiny-
lated MBP, biotinylated TrxA and the full construct
MBP-NTR1-TrxA (complexed to biot-NT) were immobi-
lized. Free biotin-binding sites were blocked with 3–5 mM
biotin. Excess biotin was removed by extensive washing. In a
separate reaction, a mixture of 4 nM biotinylated DARPin
and 5 nM SA–AP was incubated for 45–60 min at 48C in
WB. The mixture was then transferred to the plate and incu-
bated for 15 min. For competition experiments, 50–70 nM
NTR1 saturated with its (non-biotinylated) agonist NT was
included. In a control experiment, 750 nM free NT had not
caused dissociation of the immobilized receptor (data not
shown). Unbound DARPin/SA–AP complexes were washed
away, and the bound complexes were detected by following
the time course of absorbance at 405 nm upon conversion of
the AP substrate 4-nitrophenyl-phosphate (pNPP).
Size-exclusion chromatography
SEC experiments were performed using a Superdex 200 GL
10/300 column (GE Healthcare). The runs were performed in
buffer GF (25 mM Tris/pH 7.5 at 48C, 300 mM NaCl, 0.15%
CHAPS, 0.03% CHS, 0.3% DDM, 5% glycerol) at a flow
rate of 200 ml/min at 48C on an A¨kta Explorer system (GE
Healthcare). Protein elution was monitored at 280 nm.
Samples of 200 ml containing 15 mM receptor and/or 50 mM
DARPin with 5 myc-tags at the C-terminus were injected.
pD (17 kDa), SHP (49 kDa) and b-amylase (200 kDa) were
used to calibrate the column.
Affinity determination on the BioVeris system
The affinities of selected NTR1 binders were determined in
solution in a competition electrochemiluminescence
(ECL)-based assay on a BioVeris M1M Analyzer (Witney,
UK), essentially as described (Huber et al., 2007). The assay
relies on the light emission of the ‘BV-tag’, a
tris(2,20-bipyridine)ruthenium(II) complex conjugated to the
protein to be determined, upon electro-oxidation in the pre-
sence of aliphatic amines, such as 3-propylamine (Miao
et al., 2002). Neutravidin modified with the BV-tag
(neutravidin-BV) was prepared by reacting the protein with a
5-fold excess of BV-tag N-hydroxysuccinimide ester
(BV-tag-NHS) in PBS at 258C, pH 7.8, for 1 h. Unreacted
BV-tag-NHS was removed with an Amicon 15 (30 kDa
MWCO) concentrator (Millipore). The labeling stoichiometry
was found to be 1:1 based on protein concentration
determined by using the DC-assay (BioRad) and on the
BV-tag concentration determined by using an e455 of
15 400 M21 cm21.
The assay is based on immobilizing one DARPin, P28, to
magnetic beads, and detecting the binding of the GPCR–
ligand complex, itself bound to BV-tag-neutravidin via the
biotinylated ligand, in the presence of varying amounts of
DARPin competitor. Since the DARPins of interest all com-
peted for the same epitope, they could all be measured in
competition with the same immobilized DARPin P28.
To prepare DARPin P28 immobilized on streptavidin mag-
netic beads, 150 nM enzymatically biotinylated DARPin
biot-P28 (biotinylated to 60%) was incubated with 1 mg/
ml of MyOne T1 streptavidin beads (Roche) in TBS (pH 7.5
at 48C), 0.5% BSA at 48C for 2 h. Unbound DARPin was
washed away and remaining biotin binding sites were
blocked with 3 mM biotin. The competition solutions con-
tained, in a total volume of 280 ml, 0.5 nM DARPin biot-P28
immobilized on 5.5 mg/ml streptavidin magnetic beads,
10 nM NTR1, 13 nM biot-NT, 25 nM neutravidin-BV-tag
and varying concentrations of the non-biotinylated DARPins
as competitors (0–1500 nM) in 50 mM Tris (pH 7.5 at 48C),
0.5% CHAPS, 0.1% CHS and 0.1% DDM.
The competition solutions were incubated for 2 h at 48C,
then 130 ml was transferred to the BioVeris plate and the
ECL-based signal was measured in the BioVeris workstation.
The standard deviation between duplicate measurements was
,2%. The signal of NTR1/NT/SA-BVtag complex bound to
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an immobilized DARPin is:
ECL ¼ ðECLmax  ECLBGÞ  Cb
Cb;max
þ ECLBG ð1Þ
where ECL is the measured signal, ECLmax the maximal
signal in the absence of competitor, and ECLBG the signal
due to background binding. Cb is the bound receptor–
DARPin complex on the beads in the presence of competing
DARPin in solution and Cb,max the bound receptor–DARPin
complex on the beads in the absence of competing DARPin.
The data of P28 itself were first analyzed by fitting the
experimental values to an equation accounting for both the
solution and the solid phase equilibria (assuming identical
KD values for both the immobilized and the free DARPin),
essentially as derived previously (Huber et al., 2007). When
both equilibria are accounted for, Eq. (1) can be rewritten in
terms of total concentrations of the relevant species:
ECL¼ðECLmaxECLBGÞ 1
St=Itþ1

ðRtþStþItþKDÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðRtþStþItþKDÞ24ðSt=Itþ1ÞItRt
q
ðRtþItþKDÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðRtþItþKDÞ24ItRt
q
ð2Þ
where Rt is the total concentration of receptor added, St the
total concentration of soluble non-biotinylated competitor
DARPin added, It the total concentration of the DARPin
immobilized and KD the dissociation constant.
When different DARPins were tested, the affinities of the
immobilized (P28) and the free DARPins (P4 and D14)
could no longer be assumed to be identical, so a simplified
equation [Eq. (5)] was used. This derivation neglects receptor
depletion due to binding to the immobilized DARPin, which
represents a maximum of 5% of the total NTR1 in solution
and thus only marginally disrupts the equilibrium in solution
when the solution-phase KD is not extremely low. It is thus
assumed that the ECL signal is proportional to the fraction
of free receptor in solution.
ECL ¼ ðECLmax  ECLBGÞ  Rfree
Rt
þ ECLBG ð3Þ
or, after rearrangement,
ECL ¼ ECLmax  ECLmax þ ECLBG
Rt
 Csol ð4Þ
where Csol is the receptor–DARPin complex in solution. In
the simplified equation,
ECL ¼ ECLmax  ðECLmax  ECLBGÞ
2Rt
 ðSt þ Rt þ KDÞ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðSt þ Rt þ KDÞ2  4StRt
q 
ð5Þ
the symbols have the same meaning as in Eq. (2). To first
compare this simplified treatment for the measurement of
P28 itself, a value of 75 nM is obtained, as opposed to
71 nM from the more complete treatment of Eq. (2), an
acceptable error considering the many other experimental
uncertainties.
Epitope mapping
Different fragments of NTR1 were inserted between the
BamHI and HindIII sites of the vector pAT223 (see above),
resulting in a C-terminal fusion to pD. The constructs span
the following amino acids of the receptor: construct C1
[intracellular loop 3 (IL3)] Asn215-Gly264, construct C2
[IL3 to the end] Asn215-Tyr382 (plus His6-tag), construct
C3 [IL3 to extracellular loop 3 (EL3)] Asn215-Tyr309, con-
struct C4 [EL3 to the end] Cys290-Tyr382 (plus His6-tag),
construct C5 [IL3 to helix 8] Asn215-Arg356 and construct
C6 [C-terminus] Pro324-Tyr382 (plus His6-tag). Constructs
C1, C3 and C5 carried an additional tripeptide KLN before
the stop codon, originating from the HindIII site of the
vector.
A single colony of E.coli XL1-Blue, transformed with the
corresponding pAT223 construct, was grown at 378C over-
night in 2YT with 1% glucose (glc) and 100 mg/ml ampicil-
lin, resulting in an OD600 of 5–6. One milliliter of the
overnight cultures was diluted to 20 ml in 2YT with 0.1%
glc and 100 mg/ml ampicillin and grown to an OD600 of
0.6–0.7; expression was induced with 0.5 mM IPTG for
2 h. The resulting OD600 for the constructs (defined in
Results), pD-thioredoxin A (pD-TrxA) and no plasmid
(E. coli XL1-Blue alone), were as follows: 2.55 (C1), 0.55
(C2), 0.70 (C3), 0.45 (C4), 0.95 (C5), 2.60 (C4), 3.30
(pD-TrxA) and 3.0 (no plasmid). An aliquot of the
expression culture, corresponding to 5  108 cells, was
centrifuged for 5 min at 7000g and the pellet resuspended in
100 ml of a reducing loading buffer with 100 mM b-mercap-
toethanol, 1% SDS, 2 mM MgCl2 and 125 U/ml benzonase
(Novagen). The samples (25 ml) were analyzed by SDS–
PAGE and western blot after an overnight incubation at room
temperature. The biotinylated DARPin P28, complexed with
the SA–AP used for detection, was incubated for 15 min at a
concentration of 75 and 37.5 nM, respectively. Free biotin
binding sites were then blocked with 1 mM biotin by incu-
bation for at least 15 min and the biot-P28/SA–AP complex
solution was incubated with the blotting membrane for
45 min. After washing the membrane, the biot-P28/SA–AP
bound to the expressed receptor fragments was detected with
BCIP/NBT.
Fluorescence microscopy
COS-7 cells were grown in Dulbecco’s modified Eagle’s
medium in the presence of 10% (v/v) heat-inactivated fetal
calf serum (FCS) and 5% CO2 at 378C in a humidified
incubator. One day before transient transfection, 1.2  105
cells were seeded on poly-L-lysine-coated glass coverslips
(18  18 mm) in a 6-well culture plate. Cells covered with
1 ml medium were transfected with 1 mg plasmid DNA
using FuGENE HD (Roche) at 5 ml per mg DNA according
to the manufacturer’s instructions. Four to six hours later, the
transfection solution was exchanged for 2 ml medium con-
taining 10 mM SR48692 (Sanofi-Aventis), an antagonist for
NTR1 (Gully et al., 1993), or naloxone, an antagonist for the
k-opioid receptor (KOR). Twenty-four hours after the trans-
fection, the cells were fixed with 4% (w/v) paraformaldehyde
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in PBS (pH 8.0) for 10 min at room temperature and
blocked/permeabilized with PBS, 10% FCS, 0.1% saponin
for 30 min. The Myc-tagged receptors were detected with a
mouse anti-Myc antibody (Cell Signalling Technology,
#2276, 1:3000) and stained with an AlexaFluor-555-labeled
goat anti-mouse antibody (Invitrogen, A-21422, 1:10 000),
both for 1 h in PBS, 1% FCS, 0.1% saponin. DARPins fused
to the superfolder GFP (sfGFP) (Pedelacq et al., 2006) were
used at 1 mM concentration during the second incubation
step with the AlexaFluor-555-labeled antibody where indi-
cated. After washing three times with PBS for 5–10 min, the
nuclei were stained with 0.8 mg/ml 40,6-diamidino-
2-phenylindole (DAPI) in PBS for 2–3 min. The coverslips
were quickly washed with PBS, mounted with Fluoromount
G (Interchim) and sealed with nail varnish before
microscopy. Fluorescence images were acquired using a
Leica Leitz DMRXE microscope equipped with a
DFC350FX camera at 40 magnification. Colors, contrast
and brightness of the whole image were adjusted in Adobe
Photoshop.
Results
Ribosome display
DARPins that bind to functional, solubilized NTR1 were
selected by ribosome display. We chose to use the
detergent-solubilized GPCR as a target for selection over the
use of whole cells or reconstituted proteoliposomes, since
both extracellular and intracellular epitopes are accessible,
and this would be the form of relevance for structural
studies. Nevertheless, the detergent may also shield certain
epitopes and the GPCR might, at least in principle, adopt a
non-functional conformation. In order to ensure that the
GPCR is immobilized in functional form, we complexed the
receptor to a biotinylated agonist, NT, which was then bound
to coated neutravidin.
For these experiments, we used either the wild-type rat
NTR1 or a mutant, denoted D03, which had been
obtained by a novel directed evolution approach and
which expresses up to 10-fold better in E.coli, Pichia pas-
toris and mammalian cells and which is also significantly
more stable in detergent-solubilized form (Sarkar et al.,
2008).
The receptor was expressed in E.coli XL1-Blue essentially
as previously described (White et al., 2004). The efficient
assembly of NTR1 in the cytoplasmic membrane of E.coli
requires a low expression temperature (208C) and the use of
two fusion partners: maltose-binding protein (MBP) at the
N-terminus and thioredoxin (TrxA) at the C-terminus (White
et al., 2004). The purification of the solubilized active recep-
tor was performed in three chromatographic steps: (i) IMAC
using a Ni-NTA column, (ii) affinity chromatography on a
monomeric avidin column with immobilized biot-NT and
(iii) gel filtration, which separates the receptor moiety from
MBP, TrxA and TEV protease, added to cleave the fusion
partners.
The ribosome display selections from the DARPin library
(Binz et al., 2003) were performed essentially as described
previously (Hanes and Plu¨ckthun, 1997; Huber et al., 2007;
Zahnd et al., 2007) and are explained in more detail in
Materials and methods.
In order to save material, the GPCR target was immobi-
lized through its biot-NT ligand using a protein concentration
an order of magnitude lower than recommended in the stan-
dard ribosome display protocol (Hanes and Plu¨ckthun, 1997;
Huber et al., 2007; Zahnd et al., 2007). An important feature
of our immobilization strategy is the preservation of GPCR
activity, as the target protein must remain active in order to
bind to the biot-NT immobilized on the neutravidin-coated
plate. The same would not be true for other types of immo-
bilization (e.g. through a tag on the receptor), which would
not discriminate between active and inactive forms of the
receptor. Receptor immobilization via biot-NT will, however,
favor the selection of binders against the intracellular side of
the receptor since the peptide linker is short and, therefore,
the extracellular face of the bound receptor is constrained to
be in close proximity to the solid phase and probably less
accessible.
Two separate setups were tested for minimizing the selec-
tion of unspecific binders (denoted as P and D), as described
in Materials and methods. Four rounds of ribosome display
selection were sufficient (not shown) to obtain DARPins that
could be further analyzed.
Pool and single clone RIA
After four rounds of ribosome display, the enrichment of
binders for the receptor was determined by testing the
binding of in vitro translated [35S]Met-labeled DARPins to
immobilized NTR1. The percentage of binders recognizing
NTR1 in the pools increases from round to round, reaching
50% after the fourth round (not shown). Sixty clones, 30
from each of the two different selection setups (P and D)
described in Materials and methods, were randomly picked
from the last selection round and sequenced. Among them
we found 24 unique sequences which were further analyzed
in the in vitro translation assay (Fig. 1). The majority of the
selected DARPin clones specifically bind to the receptor.
Comparison of the D and P selection strategies shows that
the pre-panning step leads to more efficient selection of
specific clones (Fig. 1A), whereas using excess neutravidin
and biot-NT in solution to eliminate the unspecific binders
resulted in a slightly higher background binding (Fig. 1B).
Among the 24 unique sequences, the 12 best NTR1-
specific binders (according to the ELISA experiments) and
two negative controls, presumably recognizing streptavidin
and/or biot-NT, were chosen for further analysis.
As mentioned above, the purification of unfused NTR1
from E.coli requires a protease cleavage step and a separ-
ation of the mixture on a size exclusion column. Analyzing
the purified NTR1-fractions used for the selection by silver-
stained SDS–PAGE, only cleaved NTR1 was found, and
neither uncut full length protein (MBP-rT43NTR1-TrxA) nor
partially cleaved constructs nor the fusion partners MPB and
TrxA alone were detected in the NTR1 fraction (not shown).
Nonetheless, the selection of binders against the fusion part-
ners and/or the NTR1-fusion constructs resulting from some
minor contamination in the purified receptor could not be
excluded. We thus analyzed the [35S]Met-labeled DARPins
as single clones for binding to MBP and TrxA alone, to the
full fusion construct and to the receptor alone. Importantly,
no binding to purified MBP and TrxA could be detected
(Fig. 2). The signal arising from binding to the uncleaved
fusion protein is lower than that from the cleaved and
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purified receptor alone. We assume that steric hindrance of
DARPin binding or a less efficient receptor immobilization,
both due to the presence of the fusion proteins, might cause
the reduced signal. This result is consistent with the binding
epitope being localized to the beginning of C-terminus after
helix 7 and IL3, since TrxA might shield these regions (see
Epitope mapping below).
Specificity and selectivity of the binders
DARPins were expressed in E.coli in the presence or
absence of the biotinylation plasmid expressing BirA and
subsequently purified by IMAC. To analyze the requirements
for complex formation with the GPCR, especially with
regard to crystallization, selected DARPins were tested for
receptor binding in solution in a competition experiment.
The receptor was bound to immobilized ligand, as in ribo-
some display selections, and the binding of the biotinylated
DARPins was detected using a streptavidin-AP conjugate
(Fig. 3). Addition of an excess of the receptor to the
DARPin solution (see Materials and methods) significantly
decreased the signal for all of the binding clones, consistent
with specific binding to the GPCR. The reduction in signal
was not caused by the dissociation of the immobilized recep-
tor from the plate during the incubation steps, as the addition
of a large excess of the agonist NT alone did not signifi-
cantly lower the signal (Fig. 3). No signal was observed
when NTR1 was not immobilized. As a negative control, the
signal due to the clone P1 could neither be decreased by
competition with the receptor in solution nor by omitting the
receptor during the immobilization, consistent with the direct
ELISA binding data (Fig. 1). Another control DARPin, G3,
specific for HER2, gave just a background signal (Fig. 3).
The biotinylated DARPins could capture all three forms of
the receptor from solution—the agonist-bound form, the
antagonist-bound form and the ligand-free form—as deter-
mined in experiments with the radiolabeled ligands [3H]NT
and [3H]SR48692 (not shown). Thus, the binders do not
seem to differentiate between receptor conformations.
However, as expected, the selected binders are specific for
NTR1, as only using NTR1 and not a control GPCR (adeno-
sine A2A receptor) was a binding signal detected in a
BIAcore experiment with the DARPins immobilized on a
streptavidin chip (not shown).
Analytical size-exclusion chromatography
We used analytical gel filtration chromatography as a second
test for complex formation in solution (Fig. 4). An evolved
mutant of NTR1, denoted D03, which expresses up to
10-fold better than the wild type in E.coli and is more stable
Fig. 1. Radioimmunoassay using 24 of the unique clones selected after four
rounds of ribosome display. NTR1/biot-NT (black bars) or biot-NT alone
(grey bars) was immobilized on a neutravidin-coated ELISA plate. The
binding of the DARPins was detected by measuring the radioactivity of the
in vitro expressed and [35S]-Met-labeled binders. (A) Clones selected using
a pre-panning step to minimize non-specific binding (strategy D). (B) Clones
selected using an excess of neutravidin and biot-NT in solution to minimize
unspecific binding (strategy P).
Fig. 2. Specificity of the selected binders. Twelve selected DARPin binders
were purified and tested for binding to NTR1 (black bars), the full construct
MBP-NTR1-TrxA (dark grey bars), MBP (light grey bars) and TrxA (white
bars). The targets were immobilized on a neutravidin-coated ELISA plate.
TrxA and MBP were biotinylated directly, whereas NTR1 and
MBP-NTR1-TrxA were immobilized via biot-NT, as described in Materials
and methods.
Fig. 3. Competition ELISA experiment. Black bars: direct binding of the
DARPins to the immobilized NTR1 (no competition). Dark grey bars:
binding of the DARPins in the presence of an excess of NTR1 and NT in
solution (+NTR1/NT). Light grey bars: binding of the DARPins in the
presence of an excess of NT alone in solution (+NT). White bars:
background binding of the DARPins in the absence of the immobilized
receptor (no NTR1 immob.). For details, see Materials and methods.
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in detergents (Sarkar et al., 2008), was used in this exper-
iment. Control ELISA experiments demonstrated that the
selected DARPins recognize the D03 mutant and the wild-
type receptor equally well (not shown).
Both the GPCR and the DARPin elute mainly as single
peaks from a Sephadex 200 column at the expected molecu-
lar weight when injected separately. When the receptor is
pre-incubated with a 3-fold molar excess of the DARPin,
two elution peaks are observed. In the first peak, clearly
shifted to a higher molecular weight, both the GPCR and the
DARPin could be detected on a western blot (Fig. 4, inset),
whereas the second peak consists of the excess unbound
DARPin. The change in the elution volume corresponds well
to the size of the DARPin protein, as calculated from the
elution volume of the DARPin and the standard proteins.
Determination of the affinities in solution
The affinities in solution were assessed by equilibrium titra-
tion. Since previous experiments had shown that the best
binding DARPins all compete for the same or overlapping
epitopes, equilibrium affinities could be measured by compe-
tition with binding to one immobilized DARPin. The
binding of the receptor to the biotinylated DARPin, P28,
immobilized on streptavidin-coated magnetic beads was
detected by ECL (Huber et al., 2007) as described in
Materials and methods. The inhibition of GPCR binding to
immobilized P28 by different DARPins in solution was used
to calculate their affinities for the receptor in solution
(Fig. 5). The negative control DARPin P14 did not compete
for the binding of the receptor even at 1 mM concentration
(not shown). The KD values calculated as described in
Materials and methods were 75 nM for P28, 58 nM for P4
and 112 nM for D14 (Fig. 5). Using numerical fits with the
program DYNAFIT (Kuzmic, 1996) to the two equilibria
underlying Eq. (2), values of 67 nM for P28, 50 nM for P4
and 96 nM for D14 were obtained. It should be stressed that
no attempt had been made in these selection experiments to
maximize affinity, either by a selection strategy that empha-
sizes affinity or by an affinity maturation approach (Zahnd
et al., 2007).
Epitope mapping
In order to determine the binding epitope recognized by the
selected DARPins, we produced fragments of NTR1 as
C-terminal fusions to the well expressed and soluble pD and
probed them with one of the best binders, the selected
DARPin P28, on a western blot (Fig. 6). Control samples,
with cells carrying no expression plasmid or only expressing
pD-TrxA at high level, gave no signal in western blots (data
not shown). Receptor fragments composed of unpaired trans-
membrane helices, and thus probably exposing continuous
hydrophobic patches (Fig. 6B,C, lanes 3 and 4), were very
poorly expressed and/or were causing cell death, despite
being fused to pD (data not shown). Good expression levels,
i.e. clear bands on a Coomassie-stained gel, were obtained
only when parts of the receptor normally exposed to solvent
(IL3 or the C-terminal region) were fused to pD (Fig. 6B,
lanes 1 and 6). The C-terminal fragment of the receptor gave
a very strong signal in the western blot and a strong band in
the Coomassie-stained gel, whereas the IL3 alone produced a
weak signal, however, clearly distinguishable from the back-
ground (Fig. 6B,C lanes 1 and 6), and a clear Coomassie-
stained band. Fragment C5 (IL3 to helix 8, missing the last
24 C-terminal amino acids) was visible on the
Coomassie-stained gel as a rather weak band (Fig. 6B, lane
5); yet, it produced a fairly strong signal on the western blot
(Fig. 6C, lane 5). Among the fragments expressed at levels
not detectable in the Coomassie-stained gel, only fragment
C2 (IL3 to the end of the receptor) gave a clear signal in
the western blot (Fig. 6C, lane 2). The addition of the
C-terminal part of the receptor to the IL3 reduced the
expression of the fragments to very low levels (compare
Fig. 4. SEC using the NTR1 mutant D03 (Sarkar et al., 2008) and the
selected DARPin P28. Solid line: elution profile of a mixture of D03
(3 nmol) and the DARPin P28 (10 nmol); dashed line: elution profile of the
receptor alone; dotted line: elution profile of the DARPin P28 alone. Inset:
western blot analysis of TCA-precipitated fractions of the corresponding
peaks. Lane 1 corresponds to peak (1) of the mixture, lane 2 to the peak
labeled (2) of the GPCR and lane 3 to the DARPin run alone, peak (3). The
proteins were separated by SDS–PAGE, transferred to a PVDF membrane
and detected by a mixture of an anti-rNTR1 (R-20) antibody (Santa Cruz
Biotechnology, #sc-7598) and an anti-RGSH4 antibody (for DARPin
detection). It should be noted that the DARPin carries a 65-aa C-terminal
5-fold Myc-tag which is highly charged and presumably disordered. We
have previously observed that this significantly increases the hydrodynamic
radius of these already elongated molecules.
Fig. 5. Determination of the affinities in solution of three selected DARPins
for NTR1. Binding of the NTR1 to the DARPin P28 immobilized on
streptavidin beads was competed for by the DARPins present in solution at
concentrations ranging from 0 to 1500 nM. The fits shown were calculated
as described in Materials and methods.
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fragments C1 and C2, i.e. lanes 1 and 2), but the detection
with the DARPin is still much stronger than that of the well-
expressing IL3 construct alone.
Fluorescence microscopy
Fluorescence microscopy was used to test the binding of the
selected DARPins in mammalian cells (Fig. 7). NTR1 and,
as a control, KOR were expressed in COS7 cells. In order to
optimize the assay, we first used a well-characterized
anti-MBP DARPin (Binz et al., 2004), denoted off7, and
generated a cognate GPCR target by fusing MBP to the
C-terminus of KOR, in the cytoplasm. The expression of the
Flag-KOR-MBP-Myc-His6 construct could be detected, after
cell permeabilization, with an anti-Myc antibody, stained
with an AlexaFluor-555-labeled antibody in the red channel
as seen in Fig. 7A2. The image shows that only a subset of
the COS-7 cells had been transfected and hence produced
the GPCR-MBP fusion protein. Some of the expressing cells
showed only diffuse red staining whereas, in other cells, a
clear punctate staining was seen as well, which is likely to
correspond to an endoplasmic reticulum, Golgi or endosomal
localization of the receptor fusion. Direct staining with the
MBP-specific DARPin off7 fused to sfGFP only led to punc-
tate staining and thus the recognition of GPCR fusion loca-
lized in internal stores (Fig. 7A3). The lack of co-staining of
the more diffuse receptors, presumably at the cell surface,
with the off7-sfGFP construct might be due to some proteo-
lytic cleavage of the KOR-MBP fusion, or differences in the
degree of PFA-crosslinking in the different cell compart-
ments. In contrast to the anti-Myc antibody, which recog-
nizes a linear epitope, the DARPin off7 recognizes a
structured epitope within MBP (Binz et al., 2004) and might
thus be more sensitive to the extent of crosslinking per-
formed during the fixation step.
Following optimization of the control (KOR-MBP-Myc-
His with the anti-MBP DARPin off7-sfGFP), the DARPins
P28 and P14 fused to sfGFP were used for the detection of
the D03 mutant of NTR1. The control DARPin P14,
Fig. 6. Mapping of the binding epitope on the NTR1. Receptor fragments were expressed in E.coli and detected using SDS–PAGE and western blot.
(A) Schematic drawings of the receptor fragments 1–6. Parts of the receptor fused to pD are highlighted in red. Theoretical amino acid length of the expressed
constructs (including pD): C1, 155 aa; C2, 275 aa; C3, 188 aa; C4, 200 aa; C5, 247 aa and C6, 166 aa. MW, PageRuler marker (Bio-Rad).
(B) Coomassie-stained gel of the whole cell extracts. (C) Western blot after a transfer of the cell extract proteins to a PVDF membrane. Detection of the
expressed fragments was performed by using biot-P28/streptavidin-AP (SA–AP). Constructs C1–C6 correspond to lanes 1–6 in the Coomassie-stained gel and
on the western blot. The arrows denote bands discussed in the text.
Fig. 7. Binding of the selected DARPins to NTR1 expressed in mammalian cells detected using fluorescence microscopy. COS-7 cells were transfected with
(A) pcDNA3.1-Flag-KOR-MBP-Myc-His6, or (B and C) pcDNA3.1-D03-Myc-His6, as described in Materials and methods. In (B) and (C), two different
DARPins were tested, in (B) the negative control DARPin P14 and in (C) the specific DARPin P28. (A1–C1) Staining of the cell nuclei with DAPI, (A2–C2)
staining of the receptors using mouse anti-Myc and goat anti-mouse-AlexaFluor-555-labeled antibodies, (A3–C3) detection of the receptors using the
DARPin-sfGFP fusions indicated and (A4–C4) merged pictures from the blue, red and green channels.
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identified previously as not binding to the GPCR, but prob-
ably to neutravidin/biot-NT (Fig. 1), showed only back-
ground staining in the GFP channel, i.e. it stained both the
transfected and the non-transfected cells at equally low
levels (Fig. 7B3) and hence failed to co-localize with the red
signal originating from the Myc-tagged receptor. In contrast,
the P28 binder, shown in vitro to bind to the GPCR, exhib-
ited mostly perinuclear staining, clearly distinguishable from
the background signal, which co-localized with the anti-Myc
receptor staining (Fig. 7C2 and C4). The staining of the D03
receptor with P28-sfGFP was, however, weaker than the
KOR-MBP staining with the off7-sfGFP. The reasons for this
might be the lower affinity of P28 to the GPCR (70 nM)
than of off7 to MBP (4 nM) (Binz et al., 2004) and the
fact that the binding epitope on the NTR1 receptor is close
to the membrane, which might decrease affinity due to steric
effects. Nonetheless, while the DARPin was selected in
detergent-solubilized form, binding in whole cells can be
detected.
Discussion
To the best of our knowledge, this is the first work to
describe the generation of protein binders to a GPCR that are
derived neither from antibodies nor from ligands or natural
binding partners. Although Fab fragments are larger than
DARPins (50 versus 18 kDa) and can protrude further out
and potentially leave more space in the crystal for the
membrane-bound detergent molecules, they are built from
several domains and therefore display more conformational
flexibility than the very rigid and stable ankyrin fold, which
has been successfully used in co-crystallization of several
targets (Binz et al., 2004; Kohl et al., 2005; Schweizer et al.,
2007). In DARPins, the binding residues are located in stable
secondary structure elements and short b-turns, leading to a
rather shallow binding surface with an ideal shape comp-
lementary to folded proteins. This preference may also limit
the dynamics of the receptor, potentially leading to greater
conformational homogeneity, which is a major factor in suc-
cessful crystallization of GPCRs (Cherezov et al., 2007;
Rasmussen et al., 2007; Warne et al., 2008).
Our epitope mapping experiments (Fig. 6) are consistent
with the observation that DARPin P28 recognizes both wild-
type NTR1 and the D03 mutant equally well, since none of
the mutated amino acids is located in the epitope. The
mapping experiments also show that the minimal epitope
must lie within the sequence corresponding to the intersec-
tion of fragments C2, C5 and C6, i.e. within the 33 amino
acids after the helix 7. This part of the receptor includes the
putative helix 8. However, the recognition of C1 and C2,
relative to their low expression levels, also hints at the recog-
nition of IL3. This weak but detectable signal arising from
IL3 suggests that the binders might recognize a discontinu-
ous epitope composed of both structural elements, potentially
stabilizing this flexible region in the folded receptor. As seen
in the X-ray structures, stabilization of this region may be
important in generating high-quality crystals (Cherezov
et al., 2007; Rasmussen et al., 2007; Warne et al., 2008).
We tested whether the DARPins can distinguish among
different conformations of the receptor. The competition
ELISA (Fig. 3), based on detection of only the active recep-
tor complexed to its biotinylated agonist, showed that this
form is recognized. A further ELISA, in which DARPins
were coated, receptor was bound, and finally radioactive
agonist and antagonist were added, showed no systematic
differences that would indicate that DARPins differentiate
between both forms (data not shown). SEC experiments
(Fig. 4) demonstrate the binding of a selected DARPin to a
ligand-free receptor. Additional chromatography experiments
carried out at small scales show that the DARPins bind both
to ligand-free and to agonist-bound receptor (data not
shown). Taken together, these experiments showed that the
binders recognize the receptor bound to agonist, antagonist
and in free form, although we have not determined whether
subtle differences in affinity exist.
The selected DARPin binders recognize NTR1 in different
environments—in detergent-solubilized form (either free in
solution or immobilized on a microtiter plate or beads) and
in the native membrane of mammalian cells—as shown by
various immunoassays, fluorescence microscopy and SEC.
Owing to this versatility and reasonable affinity for the
receptor, the binders can be used for a variety of applications
such as co-crystallization and in vivo signal transduction
assays.
A frequently encountered obstacle when studying GPCRs
is the low amount of receptor available and the limited stab-
ility in detergent-solubilized form. Having evolved the recep-
tor to higher expression levels and greater stability in
detergents (Sarkar et al., 2008), this problem could be over-
come. In the present study, we show that by using our
DARPin technology and ribosome display, we could isolate
functional binders using ,10 mg NTR1. We believe that
these technologies will allow the study of other GPCRs that
have been refractory to structural and functional studies until
now, but are nevertheless of great biomedical interest.
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